Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds.
The growth of the global migraine drugs market is driven by various factors such as an increasing global geriatric population, rising prevalence of migraine, growing awareness about migraine in developing economies, rising R&D investment for the development of innovative drugs for the treatment of migraine, and increasing demand for better treatment methods for migraine.
Some of the key players in the global migraine drugs market are
Allergan Plc (Ireland)
Alder Biopharmaceuticals Inc. (US)
Pfizer Inc. (US)
GlaxoSmithKline Plc (UK)
Merck & Co. Inc. (US)
Teva Pharmaceutical Industries Ltd (Israel)
AstraZeneca Plc (UK)
Johnson & Johnson Services Inc. (US)
Amgen Inc (US)
Eli Lilly and Company
eNeura Inc
and Others
Get a Free Sample PDR @https://www.marketresearchfuture.com/sample_request/8379
Migraine is more common in women than men, majorly due to the fluctuations in the hormone levels. Approximately 12% of the US population suffered from migraine headaches in 2018. The treatment of migraine headaches is eased by the administration of preventive medications, to avoid migraine attacks and abortive medications to relieve strong and periodic pain.
Market Segmentation
The global migraine drugs market has been segmented based on type, treatment, drug class, and end user.
The global migraine drugs market has been segmented, on the basis of migraine-type into episodic migraine and chronic migraine.
The global migraine drugs market has been segmented, on the basis of treatment type, into, acute, preventive, neuromodulation, and others.
The acute segment is expected to hold the majority share of the market as the prevalence of acute migraine is high, and most of the drugs manufactured by major companies are for the treatment of acute migraine.
The global migraine drugs market has been segmented, on the basis of drug class, into beta-blockers, Angiotensin Blockers, tricyclics, anticonvulsants, triptans, and others.
